SGLT2 inhibitors in heart failure with preserved ejection fraction

Mohammed Faluk, Abdirahman Wardhere, Ravi Thakker, Fatima A. Khan

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Heart failure (HF) is a clinical syndrome due to either functional or structural impairment of the ventricular pump or filling, representing a major cause of global morbidity and mortality. Heart failure with preserved ejection fraction (HFpEF), characterized by a left ventricular ejection fraction (LVEF) of ≥50%, constitutes over half of the HF population, with a rising prevalence. Until recently, therapeutic options in treating HFpEF and reducing hospitalization and mortality remained limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promising results in this patient population. This review article explores current literature and significant clinical trials investigating the impact of sodium- SGLT2 inhibitors in patients with HFpEF.

Original languageEnglish (US)
Article number102388
JournalCurrent Problems in Cardiology
Issue number3
StatePublished - Mar 2024

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'SGLT2 inhibitors in heart failure with preserved ejection fraction'. Together they form a unique fingerprint.

Cite this